Clinical Efficacy of Erlotinib Combined with Probiotic Intervention in Treating Advanced Non-Small Cell Lung Cancer

Abstract

This study aimed to assess the clinical efficacy of erlotinib combined with probiotic intervention in treating patients with advanced non-small cell lung cancer. The control group (n = 50) received nedaplatin combined with pemetrexed, while the observation group (n = 50) received erlotinib and nedaplatin combined with probiotic intervention. The total response and disease control rates were higher in the observation group than in the control group (P < 0.05), whereas the occurrence of adverse reactions in the observation group was lower (P < 0.05). The serum levels of matrix metalloproteinases-2, angiopoietin-like-2, and miR-25 in the observation group were lower than those in the control group (P < 0.05), and the improvement rate of comprehensive quality of life was higher (P < 0.05). After therapy, CD3+, CD4+, and CD4+/CD8+ in the observation group were higher than in the control group (P < 0.05). CD8+ in the observation group was lower than in the control group (P < 0.05). Serum hemoglobin and albumin levels were higher in the observation group than in the control group (P < 0.05). Briefly, erlotinib combined with probiotic intervention can promote the nourishment state, immune function, and quality of life of patients with non-small cell lung cancer, expanding the therapeutic choices for advanced non-small cell lung cancer.